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Necrotizing fasciitis is a fulminant soft tissue infection characterized by rapid progression and high mortality. Rituximab is a
generally well-tolerated immunosuppresive medication used for B-cell malignancies and some rheumatological disorders. We
report a case of a 69-year-old male with chronic lymphocytic leukemia who suffered necrotizing fasciitis of his left lower extremity
secondary to Clostridium septicum 7 weeks after treatment with rituximab. Despite immediate intravenous antimicrobial therapy
and emergent fasciotomy with extensive debridement, his hospital course was complicated by septic shock and he required an
above-the-knee amputation. Physicians need to be aware of the possibility of necrotizing fasciitis in patients presenting with skin
infections after rituximab therapy.
1. Introduction
Necrotizing fasciitis (NF) is a rare, fulminant soft tissue
infection characterized by rapidly progressive and extensive
destruction of the skin, subcutaneous fat, and fascia [1].While
the incidence of NF is very low (0.4 cases per 100,000 adults)
[1], it is unfortunately associated with a high mortality rate,
ranging between 25 and 73% [1, 2]. Urgent and aggressive
surgical debridement is needed, as delayed or inadequate
debridement has been linked with increased mortality [2–
4]. Rituximab is an anti-CD20 monoclonal antibody that
leads to immunosuppression via depletion of CD20-positive
B lymphocytes, and is indicated for treatment of B-cell hema-
tological malignancies [5, 6] and rheumatological condi-
tions including systemic lupus erythematosus (SLE) [7] and
rheumatoid arthritis (RA) [8]. We present a case of NF that
occurred seven weeks after a course of rituximab infusions
in a patient with chronic lymphocytic leukemia (CLL), and
review similar relevant cases of rituximab-associated NF.
2. Case Report
A 69-year-old male with a history of CLL presented to the
emergency department with a 2-day history of progressively
worsening left lower limb pain, fever, chills, and malaise. He
denied any trauma to his legs, skin breaks, bug bites, nau-
sea, vomiting, weight loss, sick contacts, lymphadenopathy,
neurological deficits, or recent travel history. There was no
documented history of diabetes, tobacco use, alcoholism, or
prior severe infections.
Thepatientwas diagnosedwithCD-38negativeCLL eight
years prior to admission and was treated 2 years after initial
diagnosis with 6 cycles of bendamustine and rituximab after
which he was in complete remission. Approximately 11 weeks
prior to admission, he was retreated with a 4-week course
of rituximab for a resurgence of his CLL, characterized by
leukocytosis, anemia, thrombocytopenia, and hypogamma-
globulinemia (IgG: 379mg/dL (normal: 767–1590mg/dL)).
This course was completed 7 weeks before admission.
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Figure 1: Initial X-ray of the left tibia and fibula is displayed. There
is mild tibial plafond spurring. No other acute abnormalities are
identified.
On initial assessment, he was afebrile (36.5∘C) and other
vital signs were normal. Left lower limb examination revealed
moderate tenderness to palpation but no erythema or swell-
ing. However, within 7 hours of presentation, the patient was
noted to have a fever of 39.2∘C, and pain in his left lower
extremity worsened considerably accompanied with exten-
sive tissue induration, new erythema extending from the left
ankle to the knees, and subcutaneous emphysema.
Laboratory results were notable for white blood count
(WBC) of 5,800 c/𝜇L (4,800–10,800 c/𝜇L), absolute neutro-
phil count of 800 c/𝜇L, and platelet count of 61,000 c/𝜇L
(130,000–400,000 c/𝜇L). Lactic acid was elevated at 3.6mEq/
L (0.5–2.2mEq/L). C-reactive protein was elevated at
2.95mg/dL (0.00–0.70mg/dL). Creatine phosphokinase
(CK) level was elevated at 5185 IU/L (30–223 IU/L).
Initial X-rays of the lower extremity (Figure 1) and
lower extremity arterial duplex studies were normal. CT scan
performed three hours after initial X-rays however showed
a small amount of gas and subcutaneous fat edema in
anterolateral leg, concerning for NF (Figure 2). Two out of
four blood cultures grew Clostridium septicum by day 2.
The patient was started on intravenous broad-spectrum
antibiotics including vancomycin and piperacillin-tazo-
bactam. He underwent emergent fasciotomy of the left
lower extremity with complete excisional debridement of the
anterior compartment and counterincisions of the left dorsal
foot and left mediolateral thigh. However, he still required a
guillotine left below the knee amputation the following day.
Pathological analysis of the excised tissue showed necrotic
fibrous tissue consistent with fascia and associated necrotic
skeletal muscle.
Postoperatively, the patient was transferred to the inten-
sive care unit due to septic shock requiring norepinephrine
infusion to maintain blood pressure; this was successfully
weaned by the first postoperative day. During the next
three weeks, the patient had a total of seven debridement
Subcutaneous gas
Subcutaneous fat 
edema
Figure 2: CT scan of the left lower extremity is displayed. Small
amount of gas and subcutaneous fat edema present in anterior and
lateral leg.
procedures along with an above-the-knee amputation. He
stayed in the hospital for a total of three weeks prior to dis-
charge to a rehabilitation facility.
3. Discussion
We describe the case of a patient who developed Clostridium
septicemia manifesting as NF requiring amputation. Our
patient was elderly (69 years old) with CLL complicated
by hypogammaglobulinemia, which may itself have predis-
posed him to NF [18]; however the temporal relationship
to rituximab therapy suggests that the treatment may have
increased his susceptibility [19]. In the eight other patients we
identified in the literature, all developed NF within 2 months
of their last rituximab treatment (Table 1) which is congruent
with prior descriptions of a temporal relationship between
rituximab and severe infections in rheumatologic disease
registries [19, 20]. However a systematic review and meta-
analysis of the risk of infections in patients with lymphoma
treatedwith rituximab did not demonstrate a relative increase
in the incidence of severe infections when added to standard
chemotherapy [21], and a similar study did not find increased
risk of severe infections in RA patients [22].
Besides rituximab-induced necrotizing fasciitis, other
drug-related necrotizing fasciitis cases in immunocompro-
mised patients have been previously reported in the literature,
including associations with systemic corticosteroids [23],
tumor necrosis factor-alpha (TNF-𝛼) inhibitors [24], nons-
teroidal anti-inflammatory drugs [25], and other immuno-
suppressants such as tocilizumab [26] and bortezomib [27].
Although it is unclear whether the primary precipitating
factor for necrotizing fasciitis is from immunosuppressive
pharmacologic therapy, preexisting immunodeficiency, or
malignancy, the temporal occurrence of necrotizing fasciitis
was noted to occur closer to administration of immunosup-
pressant therapy in most cases.
NF is classified into two groups: type 1, a polymicrobial
infection from anaerobes includingClostridia, gram-negative
rods, and gram-positive cocci, and type 2, a monomicrobial
infection often due toGroupA Streptococcus [2]. Risk factors
Case Reports in Hematology 3
Ta
bl
e
1:
Ca
se
so
fp
at
ie
nt
sd
ev
elo
pi
ng
N
F
aft
er
rit
ux
im
ab
th
er
ap
y.
S/
N
St
ud
y
C
on
di
tio
n
A
ge
/s
ex
D
os
in
g
pr
ot
oc
ol
Cy
cle
,
do
se
O
ns
et
of
N
F
fro
m
la
st
do
se
O
rg
an
ism
Lo
ca
tio
n
of
N
F
C
on
cu
rr
en
t
m
ed
ic
at
io
n
C
om
or
bi
di
tie
s
O
ut
co
m
e
1
Cu
rr
en
ts
tu
dy
CL
L
69
/M
37
5m
g/
m
2
×
4
2,
4
7
w
ee
ks
Cl
os
tri
di
um
se
pt
icu
m
LL
E
N
on
e
N
on
e
Su
rv
iv
ed
2
La
zz
er
ie
ta
l.
[9
,1
0]
CL
L
44
/M
N
A
N
A
N
A
Ps
eu
do
m
on
as
ae
ru
gi
no
sa
Pe
rio
rb
ita
l
Fl
ud
ar
ab
in
e
Cy
clo
ph
os
ph
am
id
e
N
A
Su
rv
iv
ed
3
G
ue
rr
er
o
et
al
.[
11
];
W
on
g
et
al
.[
12
]
SL
E
21
/M
N
A
N
A
N
A
Ac
in
et
ob
ac
te
rb
au
m
an
ni
i
Ab
do
m
en
Bi
lfl
an
ks
Th
ig
h
Sc
ap
ul
a
St
er
oi
ds
N
A
D
ie
d
4
Kr
ie
ge
re
ta
l.
[1
3]
N
H
L,
fo
lli
cu
la
r
48
/F
37
5m
g/
m
2
(w
ee
kl
y)
1,
4
1m
on
th
Ps
eu
do
m
on
as
ae
ru
gi
no
sa
Le
ft
lo
w
er
ex
tre
m
ity
N
A
N
A
D
ie
d
5
Kr
ie
ge
re
ta
l.
[1
3]
N
H
L,
fo
lli
cu
la
r
59
/M
37
5m
g/
m
2
(w
ee
kl
y)
Ri
tu
xi
m
ab
sto
pp
ed
aft
er
3
do
se
s.
1,
3
N
A
Es
ch
er
ich
ia
co
li
(E
.c
ol
i)
Sc
ro
tu
m
Et
op
os
id
e,
ci
sp
la
tin
,
m
et
hy
lp
re
dn
iso
ne
,
cy
to
sin
e,
an
d
ar
ab
in
os
id
e
N
A
D
ie
d
6
Lo
on
ey
et
al
.
[14
]
SL
E
37
/F
37
5m
g/
m
2
×
4
(w
ee
kl
y)
1,
4
6
w
ee
ks
G
ro
up
A
St
re
pt
oc
oc
cu
s
El
bo
w
M
et
ho
tre
xa
te
St
er
oi
ds
Se
pt
ic
ar
th
rit
is
N
/A
7
Ch
en
an
d
Is
en
be
rg
[1
5]
SL
E
26
/F
1g
w
ee
kl
y
1,
2
2
m
on
th
s
Ps
eu
do
m
on
as
ae
ro
gi
no
sa
LL
E
H
yd
ro
xy
ch
lo
ro
qu
in
e
A
za
th
io
pr
in
e
Cy
clo
ph
os
ph
am
id
e
St
er
oi
d
AV
N
be
lo
w
D
ig
ita
li
sc
he
m
ia
E.
co
li
U
TI
Su
rv
iv
ed
8
M
or
ita
et
al
.
[1
6]
W
al
de
ns
tro
m
’s
m
ac
ro
gl
ob
ul
in
em
ia
76
/M
37
5m
g/
m
2
(w
ee
kl
y)
1,
1
2
w
ee
ks
Kl
eb
sie
lla
pn
eu
m
on
ia
RL
E
Bo
rt
ez
om
ib
D
ex
am
et
ha
so
ne
D
ia
rr
he
a
D
ie
d
9
Ra
gh
uv
an
sh
i
an
d
M
en
on
[1
7]
Rh
eu
m
at
oi
d
ar
th
rit
is
62
/F
N
A
1,
2
2
w
ee
ks
G
ro
up
A
St
re
pt
oc
oc
cu
s
LU
E
Pr
ed
ni
so
ne
N
A
D
ie
d
AV
N
=
av
as
cu
la
rn
ec
ro
sis
;B
il
=
bi
lat
er
al
;C
LL
=
ch
ro
ni
cl
ym
ph
oc
yt
ic
le
uk
em
ia
;F
=
fe
m
al
e;
LL
E
=
le
ft
lo
w
er
ex
tre
m
ity
;L
U
E
=
le
ft
up
pe
re
xt
re
m
ity
;M
=
m
al
e;
N
A
=
no
ta
va
ila
bl
e;
N
F
=
ne
cr
ot
iz
in
g
fa
sc
iit
is;
N
H
L
=
no
n-
H
od
gk
in
’s
ly
m
ph
om
a;
RL
E
=
rig
ht
lo
w
er
ex
tre
m
ity
;S
LE
=
sy
ste
m
ic
lu
pu
se
ry
th
em
at
os
us
;S
/N
=
se
ria
ln
um
be
r;
U
TI
=
ur
in
ar
y
tr
ac
ti
nf
ec
tio
n.
4 Case Reports in Hematology
for NF infection include immunosuppression, diabetesmelli-
tus, trauma, or recent surgery and intravenous drug use [18].
Interestingly, although polymicrobial type 1 NF is commonly
associated with immune impairment, our patient and all the
cases we identified had monomicrobial NF. This suggests
that the mechanism may have been initial bacteremia and
seeding of that organism in otherwise viable tissue rather than
overgrowth of polymicrobial bacteria in tissue with limited
blood supply that typically characterizes type 1 NF.
Monomicrobial infection is usually associatedwith gram-
positive infections; however gram-negative monomicrobial
NF is being increasingly reported [28]. Sixty-seven percent
(67%) of the cases we reviewed had gram-negative organisms
implicated. Yahav et al. in a single-center study compared
gram-negative and gram-positive monomicrobial NF and
found that gram-negative monomicrobial NF was associated
with mostly immunocompromised patients and higher mor-
tality rates [29]. Our patient had a monomicrobial infec-
tion with Clostridium septicum, a gram-positive anaerobe.
Clostridium septicum NF has been linked with underlying
malignancy, particularly colon cancer and hematological
malignancies [30]. In a recent review, 61% of adult patients
withClostridium septicumNF had gastrointestinal malignan-
cies [30]. Notably, our patient had a normal colonoscopy two
years prior to admission.
Of those reporting fatalities in our review, five of the
eight patients (63%) died. The death rate in this case series
was in the higher range of what is reported in the literature,
which may be attributable to the impaired immune response
in patients receiving anti-B-cell therapies. Lee et al. found that
patients with gram-negative NF presented with more severe
sepsis [31].
4. Conclusion
Rituximab used in conjunction with steroids and other
immunosuppressant agents may increase the risk of serious
infections such as NF; other important factors which increase
the risk of serious infections while on rituximab include
elderly age and hypogammaglobulinemia. Emergent surgical
consultation and fasciotomy should be performed, as delay
in treatment has been associated with increased mortality.
Further studies should investigate the relationship between
rituximab and NF.
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